PIK3CA and cancer: Based on the identified somatic pathogenic variants, anti-cancer drugs such as PIK3CA or MEK inhibitors could be applied as therapy, i. e., PIK3CA inhibition is clinically effective without substantial side effects in patients with PROS [35].